RhoA Regulates Resistance to Irinotecan by Regulating Membrane Transporter and Apoptosis Signaling in Colorectal Cancer

Overview

Journal Oncotarget

Specialty Oncology

Date 2016 Nov 27

PMID 27888624

Citations 9

Authors

Huang Ruihua

Zhang Mengyi

Zhao Chong

Qiu Meng

Ma Xin

Tang Qiulin

Bi Feng

Liu Ming

Affiliations

Soon will be listed here.

Abstract

Colorectal cancer (CRC) is a major cause of mortality and morbidity worldwide. While surgery remains the mainstay of treatment in early stage CRC, chemotherapy is usually given to prolong the overall survival and improve the quality of life for metastatic colorectal cancer (mCRC). But drug resistance is one of the major hurdles of mCRC treatment, and the underlying mechanisms are still largely unknown. In this study, we show that, compared with parental cells, RhoA is up-regulated in irinotecan (CPT-11)-resistant CRC cells. Furthermore, inhibition of RhoA in drug resistant cells, at least partially, rescues the resistance against irinotecan and increases the sensitivity to other chemotherapeutic drug by inhibiting expression of MDR1, MRP1and GSTP1, promotes apoptosis by suppressing the expression of BCL-XL and Bcl-2 and increasing Bax expression, and significantly decreases side population cells. Our results suggest that, in addition to survival, proliferation, migration, adhesion, cell cycle and gene transcription, RhoA is also involved in chemoresistance by regulating the expression of membrane transporter and apoptosis protein in colorectal cancer. They raise an interesting possibility that the expression of RhoA may indicate a poor prognosis due to the high probability to therapy resistance and, on the other hand, inhibition of RhoA activity and function may overcome chemoresistance and improve the effectiveness of clinical treatment of CRC.

Citing Articles

Novel inhibitor against Rac1 for therapeutic approach in prevention of breast cancer progression.

Singh A, Koley T, Vats D, Singh A, Samath E, Batra A Sci Rep. 2024; 14(1):25083.

PMID: 39443601 PMC: 11500341. DOI: 10.1038/s41598-024-75351-y.

RhoA-ROCK2 signaling possesses complex pathophysiological functions in cancer progression and shows promising therapeutic potential.

Ning Y, Zheng M, Zhang Y, Jiao Y, Wang J, Zhang S Cancer Cell Int. 2024; 24(1):339.

PMID: 39402585 PMC: 11475559. DOI: 10.1186/s12935-024-03519-7.

Comprehensive Molecular Landscape of Cetuximab Resistance in Head and Neck Cancer Cell Lines.

Gomes I, da Silva-Oliveira R, Sussuchi da Silva L, Martinho O, Evangelista A, van Helvoort Lengert A Cells. 2022; 11(1).

PMID: 35011716 PMC: 8750399. DOI: 10.3390/cells11010154.

Computational Prediction of Hot Spots and Binding Site of Inhibitor NSC23766 on Rac1 Binding With Tiam1.

Zheng C, Wu X, Zeng R, Lin L, Xu L, Li E Front Chem. 2021; 8:625437.

PMID: 33604328 PMC: 7884829. DOI: 10.3389/fchem.2020.625437.

Rho GTPases as Key Molecular Players within Intestinal Mucosa and GI Diseases.

Pradhan R, Ngo P, Martinez-Sanchez L, Neurath M, Lopez-Posadas R Cells. 2021; 10(1).

PMID: 33406731 PMC: 7823293. DOI: 10.3390/cells10010066.

References

Huang Y, Sadee W . Membrane transporters and channels in chemoresistance and -sensitivity of tumor cells. Cancer Lett. 2005; 239(2):168-82. DOI: 10.1016/j.canlet.2005.07.032. View

Gong F, Peng X, Tan B, Ge J, Chen X, Chen Y . Comparative proteomic analysis of irinotecan-sensitive colorectal carcinoma cell line and its chemoresistant counterpart. Anticancer Drugs. 2011; 22(6):500-6. DOI: 10.1097/CAD.0b013e3283408596. View

Peng X, Gong F, Wei M, Chen X, Chen Y, Cheng K . Proteomic analysis of cell lines to identify the irinotecan resistance proteins. J Biosci. 2011; 35(4):557-64. DOI: 10.1007/s12038-010-0064-9. View

Etienne-Manneville S, Hall A . Rho GTPases in cell biology. Nature. 2002; 420(6916):629-35. DOI: 10.1038/nature01148. View

Szakacs G, Annereau J, Lababidi S, Shankavaram U, Arciello A, Bussey K . Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell. 2004; 6(2):129-37. DOI: 10.1016/j.ccr.2004.06.026. View

Dean M, Fojo T, Bates S . Tumour stem cells and drug resistance. Nat Rev Cancer. 2005; 5(4):275-84. DOI: 10.1038/nrc1590. View

Siegel R, DeSantis C, Jemal A . Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014; 64(2):104-17. DOI: 10.3322/caac.21220. View

Murata T, Haisa M, Uetsuka H, Nobuhisa T, Ookawa T, Tabuchi Y . Molecular mechanism of chemoresistance to cisplatin in ovarian cancer cell lines. Int J Mol Med. 2004; 13(6):865-8. View

Gillet J, Efferth T, Steinbach D, Hamels J, DE Longueville F, Bertholet V . Microarray-based detection of multidrug resistance in human tumor cells by expression profiling of ATP-binding cassette transporter genes. Cancer Res. 2004; 64(24):8987-93. DOI: 10.1158/0008-5472.CAN-04-1978. View

10.

Sau A, Pellizzari Tregno F, Valentino F, Federici G, Caccuri A . Glutathione transferases and development of new principles to overcome drug resistance. Arch Biochem Biophys. 2010; 500(2):116-22. DOI: 10.1016/j.abb.2010.05.012. View

11.

Saltz L, Douillard J, Pirotta N, Alakl M, Gruia G, Awad L . Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard. Oncologist. 2001; 6(1):81-91. DOI: 10.1634/theoncologist.6-1-81. View

12.

Dodds H, Haaz M, Riou J, Robert J, Rivory L . Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38. J Pharmacol Exp Ther. 1998; 286(1):578-83. View

13.

Sahai E, Marshall C . RHO-GTPases and cancer. Nat Rev Cancer. 2003; 2(2):133-42. DOI: 10.1038/nrc725. View

14.

Chen Z, Pervaiz S . Bcl-2 induces pro-oxidant state by engaging mitochondrial respiration in tumor cells. Cell Death Differ. 2007; 14(9):1617-27. DOI: 10.1038/sj.cdd.4402165. View

15.

Stojcheva N, Schechtmann G, Sass S, Roth P, Florea A, Stefanski A . MicroRNA-138 promotes acquired alkylator resistance in glioblastoma by targeting the Bcl-2-interacting mediator BIM. Oncotarget. 2016; 7(11):12937-50. PMC: 4914333. DOI: 10.18632/oncotarget.7346. View

16.

Moserle L, Ghisi M, Amadori A, Indraccolo S . Side population and cancer stem cells: therapeutic implications. Cancer Lett. 2009; 288(1):1-9. DOI: 10.1016/j.canlet.2009.05.020. View

17.

Hu L, McArthur C, Jaffe R . Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. Br J Cancer. 2010; 102(8):1276-83. PMC: 2856005. DOI: 10.1038/sj.bjc.6605626. View

18.

Chen L, Gilkes D, Pan Y, Lane W, Chen J . ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage. EMBO J. 2005; 24(19):3411-22. PMC: 1276172. DOI: 10.1038/sj.emboj.7600812. View

19.

Ishii T, Teramoto S, Matsuse T . GSTP1 affects chemoresistance against camptothecin in human lung adenocarcinoma cells. Cancer Lett. 2004; 216(1):89-102. DOI: 10.1016/j.canlet.2004.05.018. View

20.

Carloni V, Mazzocca A, Mello T, Galli A, Capaccioli S . Cell fusion promotes chemoresistance in metastatic colon carcinoma. Oncogene. 2012; 32(21):2649-60. DOI: 10.1038/onc.2012.268. View